Lypsa Gems & Jewellery Limited (LYPSAGEMS.NS) Stock Competitors & Peer Comparison
See (LYPSAGEMS.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Luxury Goods Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LYPSAGEMS.NS | ₹4.92 | -1.80% | 146.8M | -1.06 | -₹4.72 | N/A |
| TITAN.NS | ₹4,231.00 | +3.75% | 3.6T | 71.67 | ₹57.05 | +0.27% |
| TITAN.BO | ₹4,226.95 | +3.63% | 3.6T | 87.43 | ₹46.74 | +0.27% |
| KALYANKJIL.BO | ₹362.20 | +2.58% | 364.7B | 27.08 | ₹13.04 | +0.42% |
| KALYANKJIL.NS | ₹362.10 | +2.55% | 364.6B | 27.01 | ₹13.07 | +0.42% |
| THANGAMAYL.NS | ₹5,520.60 | +20.26% | 149B | 42.39 | ₹113.11 | +0.26% |
| THANGAMAYL.BO | ₹5,522.20 | +20.32% | 149B | 42.41 | ₹113.04 | +0.26% |
| SKYGOLD.BO | ₹571.35 | +2.18% | 87.3B | 31.20 | ₹18.06 | N/A |
| SKYGOLD.NS | ₹571.40 | +2.09% | 87.2B | 31.15 | ₹18.08 | N/A |
| BLUESTONE.NS | ₹535.05 | +8.12% | 77.4B | 488.70 | ₹1.04 | N/A |
Stock Comparison
LYPSAGEMS.NS vs TITAN.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, TITAN.NS has a market cap of 3.6T. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while TITAN.NS trades at ₹4,231.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas TITAN.NS's P/E ratio is 71.67. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to TITAN.NS's ROE of +0.39%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to TITAN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check TITAN.NS's competition here
LYPSAGEMS.NS vs TITAN.BO Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, TITAN.BO has a market cap of 3.6T. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while TITAN.BO trades at ₹4,226.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas TITAN.BO's P/E ratio is 87.43. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to TITAN.BO's ROE of +0.39%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to TITAN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check TITAN.BO's competition here
LYPSAGEMS.NS vs KALYANKJIL.BO Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, KALYANKJIL.BO has a market cap of 364.7B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while KALYANKJIL.BO trades at ₹362.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas KALYANKJIL.BO's P/E ratio is 27.08. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to KALYANKJIL.BO's ROE of +0.25%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to KALYANKJIL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check KALYANKJIL.BO's competition here
LYPSAGEMS.NS vs KALYANKJIL.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, KALYANKJIL.NS has a market cap of 364.6B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while KALYANKJIL.NS trades at ₹362.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas KALYANKJIL.NS's P/E ratio is 27.01. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to KALYANKJIL.NS's ROE of +0.25%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to KALYANKJIL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check KALYANKJIL.NS's competition here
LYPSAGEMS.NS vs THANGAMAYL.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, THANGAMAYL.NS has a market cap of 149B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while THANGAMAYL.NS trades at ₹5,520.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas THANGAMAYL.NS's P/E ratio is 42.39. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to THANGAMAYL.NS's ROE of +0.29%. Regarding short-term risk, LYPSAGEMS.NS is less volatile compared to THANGAMAYL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check THANGAMAYL.NS's competition here
LYPSAGEMS.NS vs THANGAMAYL.BO Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, THANGAMAYL.BO has a market cap of 149B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while THANGAMAYL.BO trades at ₹5,522.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas THANGAMAYL.BO's P/E ratio is 42.41. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to THANGAMAYL.BO's ROE of +0.29%. Regarding short-term risk, LYPSAGEMS.NS is less volatile compared to THANGAMAYL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check THANGAMAYL.BO's competition here
LYPSAGEMS.NS vs SKYGOLD.BO Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, SKYGOLD.BO has a market cap of 87.3B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while SKYGOLD.BO trades at ₹571.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas SKYGOLD.BO's P/E ratio is 31.20. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to SKYGOLD.BO's ROE of +0.31%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to SKYGOLD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check SKYGOLD.BO's competition here
LYPSAGEMS.NS vs SKYGOLD.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, SKYGOLD.NS has a market cap of 87.2B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while SKYGOLD.NS trades at ₹571.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas SKYGOLD.NS's P/E ratio is 31.15. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to SKYGOLD.NS's ROE of +0.31%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to SKYGOLD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check SKYGOLD.NS's competition here
LYPSAGEMS.NS vs BLUESTONE.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, BLUESTONE.NS has a market cap of 77.4B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while BLUESTONE.NS trades at ₹535.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas BLUESTONE.NS's P/E ratio is 488.70. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to BLUESTONE.NS's ROE of +0.01%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to BLUESTONE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check BLUESTONE.NS's competition here
LYPSAGEMS.NS vs PNGJL.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, PNGJL.NS has a market cap of 74.9B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while PNGJL.NS trades at ₹549.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas PNGJL.NS's P/E ratio is 18.28. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to PNGJL.NS's ROE of +0.24%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to PNGJL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check PNGJL.NS's competition here
LYPSAGEMS.NS vs PCJEWELLER.BO Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, PCJEWELLER.BO has a market cap of 65.2B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while PCJEWELLER.BO trades at ₹9.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas PCJEWELLER.BO's P/E ratio is 10.99. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to PCJEWELLER.BO's ROE of +0.10%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to PCJEWELLER.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check PCJEWELLER.BO's competition here
LYPSAGEMS.NS vs PCJEWELLER.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, PCJEWELLER.NS has a market cap of 65.1B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while PCJEWELLER.NS trades at ₹9.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas PCJEWELLER.NS's P/E ratio is 10.98. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to PCJEWELLER.NS's ROE of +0.10%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to PCJEWELLER.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check PCJEWELLER.NS's competition here
LYPSAGEMS.NS vs ETHOSLTD.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, ETHOSLTD.NS has a market cap of 63B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while ETHOSLTD.NS trades at ₹2,380.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas ETHOSLTD.NS's P/E ratio is 65.26. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to ETHOSLTD.NS's ROE of +0.08%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to ETHOSLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check ETHOSLTD.NS's competition here
LYPSAGEMS.NS vs ETHOSLTD.BO Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, ETHOSLTD.BO has a market cap of 62.7B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while ETHOSLTD.BO trades at ₹2,374.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas ETHOSLTD.BO's P/E ratio is 64.54. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to ETHOSLTD.BO's ROE of +0.08%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to ETHOSLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check ETHOSLTD.BO's competition here
LYPSAGEMS.NS vs SENCO.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, SENCO.NS has a market cap of 56.3B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while SENCO.NS trades at ₹344.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas SENCO.NS's P/E ratio is 9.79. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to SENCO.NS's ROE of +0.27%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to SENCO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check SENCO.NS's competition here
LYPSAGEMS.NS vs SENCO.BO Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, SENCO.BO has a market cap of 56.2B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while SENCO.BO trades at ₹344.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas SENCO.BO's P/E ratio is 9.79. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to SENCO.BO's ROE of +0.27%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to SENCO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check SENCO.BO's competition here
LYPSAGEMS.NS vs GOLDIAM.BO Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, GOLDIAM.BO has a market cap of 49.3B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while GOLDIAM.BO trades at ₹430.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas GOLDIAM.BO's P/E ratio is 28.92. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to GOLDIAM.BO's ROE of +0.19%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to GOLDIAM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check GOLDIAM.BO's competition here
LYPSAGEMS.NS vs GOLDIAM.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, GOLDIAM.NS has a market cap of 49.2B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while GOLDIAM.NS trades at ₹431.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas GOLDIAM.NS's P/E ratio is 28.77. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to GOLDIAM.NS's ROE of +0.19%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to GOLDIAM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check GOLDIAM.NS's competition here
LYPSAGEMS.NS vs VAIBHAVGBL.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, VAIBHAVGBL.NS has a market cap of 38.5B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while VAIBHAVGBL.NS trades at ₹232.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas VAIBHAVGBL.NS's P/E ratio is 14.67. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to VAIBHAVGBL.NS's ROE of +0.18%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to VAIBHAVGBL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check VAIBHAVGBL.NS's competition here
LYPSAGEMS.NS vs VAIBHAVGBL.BO Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, VAIBHAVGBL.BO has a market cap of 38.2B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while VAIBHAVGBL.BO trades at ₹232.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas VAIBHAVGBL.BO's P/E ratio is 14.53. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to VAIBHAVGBL.BO's ROE of +0.18%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to VAIBHAVGBL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check VAIBHAVGBL.BO's competition here
LYPSAGEMS.NS vs KDDL.BO Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, KDDL.BO has a market cap of 34.4B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while KDDL.BO trades at ₹2,935.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas KDDL.BO's P/E ratio is 41.38. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to KDDL.BO's ROE of +0.08%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to KDDL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check KDDL.BO's competition here
LYPSAGEMS.NS vs KDDL.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, KDDL.NS has a market cap of 34.2B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while KDDL.NS trades at ₹2,946.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas KDDL.NS's P/E ratio is 41.20. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to KDDL.NS's ROE of +0.08%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to KDDL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check KDDL.NS's competition here
LYPSAGEMS.NS vs RAJESHEXPO.BO Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, RAJESHEXPO.BO has a market cap of 32.5B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while RAJESHEXPO.BO trades at ₹104.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas RAJESHEXPO.BO's P/E ratio is 28.91. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to RAJESHEXPO.BO's ROE of +0.01%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to RAJESHEXPO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check RAJESHEXPO.BO's competition here
LYPSAGEMS.NS vs RAJESHEXPO.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, RAJESHEXPO.NS has a market cap of 32.3B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while RAJESHEXPO.NS trades at ₹103.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas RAJESHEXPO.NS's P/E ratio is 28.71. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to RAJESHEXPO.NS's ROE of +0.01%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to RAJESHEXPO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check RAJESHEXPO.NS's competition here
LYPSAGEMS.NS vs DPABHUSHAN.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, DPABHUSHAN.NS has a market cap of 21.3B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while DPABHUSHAN.NS trades at ₹931.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas DPABHUSHAN.NS's P/E ratio is 10.26. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to DPABHUSHAN.NS's ROE of +0.44%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to DPABHUSHAN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check DPABHUSHAN.NS's competition here
LYPSAGEMS.NS vs BRIGHOTEL.BO Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, BRIGHOTEL.BO has a market cap of 19.7B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while BRIGHOTEL.BO trades at ₹61.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas BRIGHOTEL.BO's P/E ratio is 36.58. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to BRIGHOTEL.BO's ROE of N/A. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to BRIGHOTEL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check BRIGHOTEL.BO's competition here
LYPSAGEMS.NS vs AAYUSHBULL.BO Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, AAYUSHBULL.BO has a market cap of 18.1B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while AAYUSHBULL.BO trades at ₹1,178.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas AAYUSHBULL.BO's P/E ratio is 229.54. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to AAYUSHBULL.BO's ROE of N/A. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to AAYUSHBULL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check AAYUSHBULL.BO's competition here
LYPSAGEMS.NS vs SHANTIGOLD.BO Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, SHANTIGOLD.BO has a market cap of 16.2B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while SHANTIGOLD.BO trades at ₹223.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas SHANTIGOLD.BO's P/E ratio is 10.56. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to SHANTIGOLD.BO's ROE of +0.37%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to SHANTIGOLD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check SHANTIGOLD.BO's competition here
LYPSAGEMS.NS vs SHANTIGOLD.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, SHANTIGOLD.NS has a market cap of 16.1B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while SHANTIGOLD.NS trades at ₹222.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas SHANTIGOLD.NS's P/E ratio is 10.51. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to SHANTIGOLD.NS's ROE of +0.37%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to SHANTIGOLD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check SHANTIGOLD.NS's competition here
LYPSAGEMS.NS vs TBZ.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, TBZ.NS has a market cap of 11.8B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while TBZ.NS trades at ₹175.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas TBZ.NS's P/E ratio is 5.86. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to TBZ.NS's ROE of +0.28%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to TBZ.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check TBZ.NS's competition here
LYPSAGEMS.NS vs TBZ.BO Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, TBZ.BO has a market cap of 11.8B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while TBZ.BO trades at ₹174.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas TBZ.BO's P/E ratio is 5.85. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to TBZ.BO's ROE of +0.28%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to TBZ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check TBZ.BO's competition here
LYPSAGEMS.NS vs MOTISONS.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, MOTISONS.NS has a market cap of 11.7B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while MOTISONS.NS trades at ₹11.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas MOTISONS.NS's P/E ratio is 18.26. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to MOTISONS.NS's ROE of +0.14%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to MOTISONS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check MOTISONS.NS's competition here
LYPSAGEMS.NS vs RGL.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, RGL.NS has a market cap of 11.1B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while RGL.NS trades at ₹102.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas RGL.NS's P/E ratio is 45.03. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to RGL.NS's ROE of +0.05%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to RGL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check RGL.NS's competition here
LYPSAGEMS.NS vs RGL.BO Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, RGL.BO has a market cap of 11B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while RGL.BO trades at ₹102.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas RGL.BO's P/E ratio is 44.80. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to RGL.BO's ROE of +0.05%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to RGL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check RGL.BO's competition here
LYPSAGEMS.NS vs MVGJL.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, MVGJL.NS has a market cap of 7.5B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while MVGJL.NS trades at ₹153.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas MVGJL.NS's P/E ratio is 6.56. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to MVGJL.NS's ROE of +0.15%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to MVGJL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check MVGJL.NS's competition here
LYPSAGEMS.NS vs MVGJL.BO Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, MVGJL.BO has a market cap of 7.5B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while MVGJL.BO trades at ₹155.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas MVGJL.BO's P/E ratio is 6.55. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to MVGJL.BO's ROE of +0.15%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to MVGJL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check MVGJL.BO's competition here
LYPSAGEMS.NS vs RADHIKAJWE.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, RADHIKAJWE.NS has a market cap of 6.8B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while RADHIKAJWE.NS trades at ₹57.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas RADHIKAJWE.NS's P/E ratio is 9.08. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to RADHIKAJWE.NS's ROE of +0.21%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to RADHIKAJWE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check RADHIKAJWE.NS's competition here
LYPSAGEMS.NS vs RADHIKAJWE.BO Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, RADHIKAJWE.BO has a market cap of 6.8B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while RADHIKAJWE.BO trades at ₹57.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas RADHIKAJWE.BO's P/E ratio is 9.08. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to RADHIKAJWE.BO's ROE of +0.21%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to RADHIKAJWE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check RADHIKAJWE.BO's competition here
LYPSAGEMS.NS vs RBZJEWEL.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, RBZJEWEL.NS has a market cap of 5B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while RBZJEWEL.NS trades at ₹125.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas RBZJEWEL.NS's P/E ratio is 9.17. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to RBZJEWEL.NS's ROE of +0.21%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to RBZJEWEL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check RBZJEWEL.NS's competition here
LYPSAGEMS.NS vs LGHL.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, LGHL.NS has a market cap of 4.8B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while LGHL.NS trades at ₹233.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas LGHL.NS's P/E ratio is -828.93. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to LGHL.NS's ROE of +0.15%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to LGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check LGHL.NS's competition here
LYPSAGEMS.NS vs SILGO.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, SILGO.NS has a market cap of 2.1B. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while SILGO.NS trades at ₹81.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas SILGO.NS's P/E ratio is 32.34. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to SILGO.NS's ROE of +0.06%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to SILGO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check SILGO.NS's competition here
LYPSAGEMS.NS vs MOKSH.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, MOKSH.NS has a market cap of 970.7M. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while MOKSH.NS trades at ₹11.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas MOKSH.NS's P/E ratio is 9.27. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to MOKSH.NS's ROE of +0.09%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to MOKSH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check MOKSH.NS's competition here
LYPSAGEMS.NS vs EFORU.BO Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, EFORU.BO has a market cap of 475.6M. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while EFORU.BO trades at ₹85.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas EFORU.BO's P/E ratio is 54.86. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to EFORU.BO's ROE of +0.47%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to EFORU.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check EFORU.BO's competition here
LYPSAGEMS.NS vs RRETAIL.BO Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, RRETAIL.BO has a market cap of 438.9M. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while RRETAIL.BO trades at ₹2.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas RRETAIL.BO's P/E ratio is 93.33. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to RRETAIL.BO's ROE of +0.00%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to RRETAIL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check RRETAIL.BO's competition here
LYPSAGEMS.NS vs KANANIIND.BO Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, KANANIIND.BO has a market cap of 302.7M. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while KANANIIND.BO trades at ₹1.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas KANANIIND.BO's P/E ratio is 17.00. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to KANANIIND.BO's ROE of +0.04%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to KANANIIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check KANANIIND.BO's competition here
LYPSAGEMS.NS vs KANANIIND.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, KANANIIND.NS has a market cap of 298.8M. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while KANANIIND.NS trades at ₹1.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas KANANIIND.NS's P/E ratio is 16.78. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to KANANIIND.NS's ROE of +0.04%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to KANANIIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check KANANIIND.NS's competition here
LYPSAGEMS.NS vs GOENKA.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, GOENKA.NS has a market cap of 259.9M. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while GOENKA.NS trades at ₹0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas GOENKA.NS's P/E ratio is -27.33. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to GOENKA.NS's ROE of -0.01%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to GOENKA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check GOENKA.NS's competition here
LYPSAGEMS.NS vs ZODJRDMKJ.NS Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, ZODJRDMKJ.NS has a market cap of 164.9M. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while ZODJRDMKJ.NS trades at ₹31.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas ZODJRDMKJ.NS's P/E ratio is 24.13. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to ZODJRDMKJ.NS's ROE of +0.05%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to ZODJRDMKJ.NS. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check ZODJRDMKJ.NS's competition here
LYPSAGEMS.NS vs LYPSAGEMS.BO Comparison June 2026
LYPSAGEMS.NS plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LYPSAGEMS.NS stands at 146.8M. In comparison, LYPSAGEMS.BO has a market cap of 146.8M. Regarding current trading prices, LYPSAGEMS.NS is priced at ₹4.92, while LYPSAGEMS.BO trades at ₹4.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LYPSAGEMS.NS currently has a P/E ratio of -1.06, whereas LYPSAGEMS.BO's P/E ratio is -1.06. In terms of profitability, LYPSAGEMS.NS's ROE is +0.10%, compared to LYPSAGEMS.BO's ROE of +0.10%. Regarding short-term risk, LYPSAGEMS.NS is more volatile compared to LYPSAGEMS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for LYPSAGEMS.NS.Check LYPSAGEMS.BO's competition here